U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Low urinary cyclic AMP response to PTH administration

MedGen UID:
350345
Concept ID:
C1864105
Finding
HPO: HP:0003456

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVLow urinary cyclic AMP response to PTH administration

Conditions with this feature

Pseudohypoparathyroidism type 1B
MedGen UID:
350343
Concept ID:
C1864100
Disease or Syndrome
Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.
Pseudohypoparathyroidism type 1C
MedGen UID:
420958
Concept ID:
C2932716
Disease or Syndrome
Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.
Pseudohypoparathyroidism type I A
MedGen UID:
488447
Concept ID:
C3494506
Disease or Syndrome
Disorders of GNAS inactivation include the phenotypes pseudohypoparathyroidism Ia, Ib, and Ic (PHP-Ia, -Ib, -Ic), pseudopseudohypoparathyroidism (PPHP), progressive osseous heteroplasia (POH), and osteoma cutis (OC). PHP-Ia and PHP-Ic are characterized by: End-organ resistance to endocrine hormones including parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), gonadotropins (LH and FSH), growth hormone-releasing hormone (GHRH), and CNS neurotransmitters (leading to obesity and variable degrees of intellectual disability and developmental delay); and The Albright hereditary osteodystrophy (AHO) phenotype (short stature, round facies, and subcutaneous ossifications) and brachydactyly type E (shortening mainly of the 4th and/or 5th metacarpals and metatarsals and distal phalanx of the thumb). Although PHP-Ib is characterized principally by PTH resistance, some individuals also have partial TSH resistance and mild features of AHO (e.g., brachydactyly). PPHP, a more limited form of PHP-Ia, is characterized by various manifestations of the AHO phenotype without the hormone resistance or obesity. POH and OC are even more restricted variants of PPHP: POH consists of dermal ossification beginning in infancy, followed by increasing and extensive bone formation in deep muscle and fascia. OC consists of extra-skeletal ossification that is limited to the dermis and subcutaneous tissues.

Recent clinical studies

Etiology

Yu EW, Neer RM, Lee H, Wyland JJ, de la Paz AV, Davis MC, Okazaki M, Finkelstein JS
Bone 2011 Apr 1;48(4):713-9. Epub 2010 Nov 24 doi: 10.1016/j.bone.2010.11.012. PMID: 21111078Free PMC Article
Schwille PO, Schmiedl A, Herrmann U, Schwille R, Fink E, Manoharan M
Methods Find Exp Clin Pharmacol 1997 Jul-Aug;19(6):417-27. PMID: 9385591
Stone MD, Hosking DJ, Garcia-Himmelstine C, White DA, Rosenblum D, Worth HG
Bone 1993 Sep-Oct;14(5):727-35. doi: 10.1016/8756-3282(93)90204-n. PMID: 8268047
D'Amour P, Gascon-Barré M, Dufresne L, Perreault JP
Clin Endocrinol (Oxf) 1984 Nov;21(5):549-62. doi: 10.1111/j.1365-2265.1984.tb01394.x. PMID: 6094046
Heath H 3rd, Purnell DC
J Lab Clin Med 1980 Dec;96(6):974-84. PMID: 6253580

Diagnosis

Seki T, Yamamoto M, Kimura H, Tsuiki M, Ono M, Miki N, Takano K, Sato K
Endocr J 2010;57(8):735-44. Epub 2010 May 25 doi: 10.1507/endocrj.k10e-097. PMID: 20505259
Tsang RC, Chen IW, McEnery P, Brown DR, Johnson JR, Lesniewicz J
J Pediatr 1976 Feb;88(2):250-6. doi: 10.1016/s0022-3476(76)80990-0. PMID: 175144

Therapy

Yu EW, Neer RM, Lee H, Wyland JJ, de la Paz AV, Davis MC, Okazaki M, Finkelstein JS
Bone 2011 Apr 1;48(4):713-9. Epub 2010 Nov 24 doi: 10.1016/j.bone.2010.11.012. PMID: 21111078Free PMC Article
Kruse K
J Pediatr 1995 May;126(5 Pt 1):736-41. doi: 10.1016/s0022-3476(95)70401-9. PMID: 7751997
Stone MD, Hosking DJ, Garcia-Himmelstine C, White DA, Rosenblum D, Worth HG
Bone 1993 Sep-Oct;14(5):727-35. doi: 10.1016/8756-3282(93)90204-n. PMID: 8268047
Law WM Jr, Heath H 3rd
J Clin Invest 1983 Sep;72(3):1106-13. doi: 10.1172/JCI111035. PMID: 6309905Free PMC Article
Heath H 3rd, Purnell DC
J Lab Clin Med 1980 Dec;96(6):974-84. PMID: 6253580

Prognosis

Rubinger D, Friedlaender MM, Silver J, Wald H, Shumart T, Popovtzer MM
Miner Electrolyte Metab 1988;14(5):283-7. PMID: 2845240

Clinical prediction guides

Yu EW, Neer RM, Lee H, Wyland JJ, de la Paz AV, Davis MC, Okazaki M, Finkelstein JS
Bone 2011 Apr 1;48(4):713-9. Epub 2010 Nov 24 doi: 10.1016/j.bone.2010.11.012. PMID: 21111078Free PMC Article
Seki T, Yamamoto M, Kimura H, Tsuiki M, Ono M, Miki N, Takano K, Sato K
Endocr J 2010;57(8):735-44. Epub 2010 May 25 doi: 10.1507/endocrj.k10e-097. PMID: 20505259
Fraher LJ, Hodsman AB, Jonas K, Saunders D, Rose CI, Henderson JE, Hendy GN, Goltzman D
J Clin Endocrinol Metab 1992 Aug;75(2):417-23. doi: 10.1210/jcem.75.2.1322424. PMID: 1322424

Supplemental Content

Table of contents

    Clinical resources

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...